Charis Eng

List of Publications by Year
in descending order

620	59,902	729 120	1413 221
papers	citations	h-index	g-index

637	637	637	40129
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Characterizing dermatologic findings among patients with PTEN hamartoma tumor syndrome: Results of a multicenter cohort study. Journal of the American Academy of Dermatology, 2023, 89, 90-98.	0.6	3
2	Brief Report: Role of Parent-Reported Executive Functioning and Anxiety in Insistence on Sameness in Individuals with Germline PTEN Mutations. Journal of Autism and Developmental Disorders, 2022, 52, 414-422.	1.7	9
3	Endoscopic Findings in Patients With PTEN Hamartoma Tumor Syndrome Undergoing Surveillance. Journal of Clinical Gastroenterology, 2022, 56, e183-e188.	1.1	4
4	Agingâ€related cell typeâ€specific pathophysiologic immune responses that exacerbate disease severity in aged COVIDâ€19 patients. Aging Cell, 2022, 21, e13544.	3.0	11
5	Fecal microbiota of adolescent and young adult cancer survivors and metabolic syndrome: an exploratory study. Pediatric Hematology and Oncology, 2022, 39, 629-643.	0.3	1
6	Distinct metabolic profiles associated with autism spectrum disorder versus cancer in individuals with germline PTEN mutations. Npj Genomic Medicine, 2022, 7, 16.	1.7	8
7	One Size Does Not Fit All: Breast Cancer in Young Women. Clinical Cancer Research, 2022, , OF1-OF1.	3.2	0
8	Shape shifting: The multiple conformational substates of the <scp>PTEN</scp> Nâ€terminal <scp>PIP₂</scp>â€binding domain. Protein Science, 2022, 31, e4308.	3.1	6
9	Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1351-1358.	1.1	3
10	Structureâ€based Computational Modeling of Germline PTEN Mutations in Cancer and Autism Risk: Implications for Therapeutic Targeting. FASEB Journal, 2022, 36, .	0.2	0
11	A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. Human Molecular Genetics, 2022, 31, 3393-3404.	1.4	10
12	A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCv8) and a polygenic risk score (PRS) for diverse ancestries.. Journal of Clinical Oncology, 2022, 40, 557-557.	0.8	1
13	Development and Progression of Thyroid Disease in PTEN Hamartoma Tumor Syndrome: Refined Surveillance Recommendations. Thyroid, 2022, 32, 1094-1100.	2.4	5
14	Oh GxE! The Complexity of Body Mass Index and Colon Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 5-6.	3.0	3
15	Cytoplasmic-predominant Pten increases microglial activation and synaptic pruning in a murine model with autism-like phenotype. Molecular Psychiatry, 2021, 26, 1458-1471.	4.1	39
16	Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Lancet Diabetes and Endocrinology,the, 2021, 9, 13-21.	5.5	37
17	PTEN Hamartoma Tumor Syndrome: A Case of Renal Cell Carcinoma in a Young Female. Urology, 2021, 148, 113-117.	0.5	3
18	Germline EGFR variants are over-represented in adolescents and young adults (AYA) with adrenocortical carcinoma. Human Molecular Genetics, 2021, 29, 3679-3690.	1.4	6

#	Article	IF	Citations
19	Cross-level analysis of molecular and neurobehavioral function in a prospective series of patients with germline heterozygous PTEN mutations with and without autism. Molecular Autism, 2021, 12, 5.	2.6	9
20	On the shoulders of giants. Human Molecular Genetics, 2021, 30, 3-4.	1.4	0
21	Comprehensive characterization of proteinâ€“protein interactions perturbed by disease mutations. Nature Genetics, 2021, 53, 342-353.	9.4	109
22	Interplay Between Class II HLA Genotypes and the Microbiome and Immune Phenotypes in Individuals With PTEN Hamartoma Tumor Syndrome. JCO Precision Oncology, 2021, 5, 357-369.	1.5	2
23	Non-canonical role of wild-type SEC23B in the cellular stress response pathway. Cell Death and Disease, 2021, 12, 304.	2.7	3
24	A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations. Contemporary Clinical Trials Communications, 2021, 21, 100733.	0.5	11
25	mTOR inhibitors reduce enteropathy, intestinal bleeding and colectomy rate in patients with juvenile polyposis of infancy with PTEN-BMPR1A deletion. Human Molecular Genetics, 2021, 30, 1273-1282.	1.4	13
26	Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer. Genome Medicine, 2021, 13, 60.	3.6	101
27	The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane. IScience, 2021, 24, 102438.	1.9	30
28	Ancestrally unbiased polygenic breast cancer (BC) risk assessment.. Journal of Clinical Oncology, 2021, 39, 10502-10502.	0.8	3
29	Germline nuclear-predominant Pten murine model exhibits impaired social and perseverative behavior, microglial activation, and increased oxytocinergic activity. Molecular Autism, 2021, 12, 41.	2.6	11
30	Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Microbiomes in Male Infertility. European Urology, 2021, 79, 826-836.	0.9	94
31	Transcriptome-(phospho)proteome characterization of brain of a germline model of cytoplasmic-predominant Pten expression with autism-like phenotypes. Npj Genomic Medicine, 2021, 6, 42.	1.7	3
32	Maternal genetics influences fetal neurodevelopment and postnatal autism spectrum disorder-like phenotype by modulating in-utero immunosuppression. Translational Psychiatry, 2021, 11, 348.	2.4	12
33	Redefining the PTEN promoter: identification of novel upstream transcription start regions. Human Molecular Genetics, 2021, 30, 2135-2148.	1.4	3
34	Multimodal single-cell omics analysis identifies epitheliumâ€“immune cell interactions and immune vulnerability associated with sex differences in COVID-19. Signal Transduction and Targeted Therapy, 2021, 6, 292.	7.1	13
35	Psychiatric Characteristics Across Individuals With PTEN Mutations. Frontiers in Psychiatry, 2021, 12, 672070.	1.3	9
36	The role of genetic polymorphisms in executive functioning performance in temporal lobe epilepsy. Epilepsy and Behavior, 2021, 121, 108088.	0.9	3

#	Article	IF	Citations
37	Reply to Eugenio Ventimiglia, Edoardo Pozzi, Massimo Alfano, Francesco Montorsi, and Andrea Saloniaâ€™s Letter to the Editor re: Scott D. Lundy, Naseer Sangwan, Neel V. Parekh, et al. Functional and Taxonomic Dysbiosis of the Gut, Urine, and Semen Microbiomes in Male Infertility. Eur Urol 2021;79:826â€“36. European Urology, 2021, 80, e55-e56.	0.9	2
38	Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2038-2043.	1.1	6
39	Toward better characterization of restricted and repetitive behaviors in individuals with germline heterozygous PTEN mutations. American Journal of Medical Genetics, Part A, 2021, 185, 3401-3410.	0.7	2
40	Microbiomic profiles of bile in patients with benign and malignant pancreaticobiliary disease.. Journal of Clinical Oncology, 2021, 39, 417-417.	0.8	1
41	My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype. Genome Biology, 2021, 22, 53.	3.8	11
42	The Clinical Spectrum of PTEN Mutations. Annual Review of Medicine, 2020, 71, 103-116.	5.0	134
43	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. Menopause, 2020, 27, 156-161.	0.8	5
44	Cancer (Epi)Genomics Comes of Age. Human Molecular Genetics, 2020, 29, R127-R127.	1.4	0
45	Early-onset renal cell carcinoma in PTEN harmatoma tumour syndrome. Npj Genomic Medicine, 2020, 5, 40.	1.7	9
46	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2020, 159, 820-826.	0.6	10
47	New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Medicine, 2020, 18, 216.	2.3	304
48	WWP1 germline variants are associated with normocephalic autism spectrum disorder. Cell Death and Disease, 2020, 11, 529.	2.7	5
49	Metabolic stress regulates genome-wide transcription in a PTEN-dependent manner. Human Molecular Genetics, 2020, 29, 2736-2745.	1.4	2
50	Verbal memory dysfunction is associated with alterations in brain transcriptome in dominant temporal lobe epilepsy. Epilepsia, 2020, 61, 2203-2213.	2.6	7
51	Alternative splicing landscape of the neural transcriptome in a cytoplasmic-predominant Pten expression murine model of autism-like Behavior. Translational Psychiatry, 2020, 10, 380.	2.4	15
52	Comprehensive germline genomic profiles of children, adolescents and young adults with solid tumors. Nature Communications, 2020, 11, 2206.	5.8	38
53	Learning to Detect Brain Lesions from Noisy Annotations. , 2020, 2020, 1910-1914.		5
54	WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition. New England Journal of Medicine, 2020, 382, 2103-2116.	13.9	49

#	Article	IF	Citations
55	PTEN hamartoma tumour syndrome: what happens when there is no PTEN germline mutation?. Human Molecular Genetics, 2020, 29, R150-R157.	1.4	13
56	Decreased nuclear Pten in neural stem cells contributes to deficits in neuronal maturation. Molecular Autism, 2020, 11, 43.	2.6	10
57	Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. Human Molecular Genetics, 2020, 29, R186-R196.	1.4	7
58	Germline PTEN mutations are associated with a skewed peripheral immune repertoire in humans and mice. Human Molecular Genetics, 2020, 29, 2353-2364.	1.4	8
59	Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes. PLoS Computational Biology, 2020, 16, e1007701.	1.5	32
60	The â€œAPCsâ€•of PTCs: Adenomatous Polyposis Syndrome and the Thyroid. Thyroid, 2020, 30, 355-356.	2.4	0
61	Target identification among known drugs by deep learning from heterogeneous networks. Chemical Science, 2020, 11, 1775-1797.	3.7	193
62	Copy Number Variation and Clinical Outcomes in Patients With GermlinePTENMutations. JAMA Network Open, 2020, 3, e1920415.	2.8	19
63	PTEN in Hereditary and Sporadic Cancer. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036087.	2.9	28
64	An Integrated Deep-Mutational-Scanning Approach Provides Clinical Insights on PTEN Genotype-Phenotype Relationships. American Journal of Human Genetics, 2020, 106, 818-829.	2.6	38
65	A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. PLoS Biology, 2020, 18, e3000970.	2.6	139
66	Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. Endocrine Connections, 2020, 9, 489-497.	0.8	17
67	Bacteriome and mycobiome and bacteriome-mycobiome interactions in head and neck squamous cell carcinoma. Oncotarget, 2020, 11, 2375-2386.	0.8	27
68	Pharmacogenomics: An evolving clinical tool for precision medicine. Cleveland Clinic Journal of Medicine, 2020, 87, 91-99.	0.6	34
69	Investigating the Link between Lynch Syndrome and Breast Cancer. The Journal of Breast Health, 2020, 16, 106-109.	0.4	30
70	Passing of the baton. Endocrine-Related Cancer, 2020, 27, E7-E8.	1.6	0
71	Identification of nuclear export signal in KLLN suggests potential role in proteasomal degradation in cancer cells. Oncotarget, 2020, 11, 4625-4636.	0.8	3
72	Outcomes after Micronized Fat Adipose Transfer for Glenohumeral Joint Arthritis and Rotator Cuff Pathology: a Case Series of 18 Shoulders. Muscles, Ligaments and Tendons Journal, 2020, 10, 393.	0.1	3

#	Article	IF	Citations
73	Title is missing!. , 2020, 18, e3000970.		0
74	Title is missing!. , 2020, 18, e3000970.		0
75	Title is missing!. , 2020, 18, e3000970.		0
76	Title is missing!. , 2020, 18, e3000970.		0
77	Title is missing!. , 2020, 18, e3000970.		0
78	Title is missing!. , 2020, 18, e3000970.		0
79	Title is missing!. , 2020, 18, e3000970.		0
80	Pheochromocytoma and Paraganglioma. New England Journal of Medicine, 2019, 381, 552-565.	13.9	437
81	Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy. JAMA Network Open, 2019, 2, e198898.	2.8	80
82	A genome-wide positioning systems network algorithm for in silico drug repurposing. Nature Communications, 2019, 10, 3476.	5.8	134
83	Neurobehavioral phenotype of autism spectrum disorder associated with germline heterozygous mutations in PTEN. Translational Psychiatry, 2019, 9, 253.	2.4	67
84	IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5573-5584.	1.8	14
85	183.â€ƒMICROBIOME IN AORTITIS. Rheumatology, 2019, 58, .	0.9	2
86	184.â€ƒTHE MICROBIOME OF TEMPORAL ARTERIES. Rheumatology, 2019, 58, .	0.9	0
87	Largescale population genomics versus deep phenotyping: Brute force or elegant pragmatism towards precision medicine. Npj Genomic Medicine, 2019, 4, 6.	1.7	20
88	Distinct Alterations in Tricarboxylic Acid Cycle Metabolites Associate with Cancer and Autism Phenotypes in Cowden Syndrome and Bannayan-Riley-Ruvalcaba Syndrome. American Journal of Human Genetics, 2019, 105, 813-821.	2.6	17
89	Constitutional mislocalization of Pten drives precocious maturation in oligodendrocytes and aberrant myelination in model of autism spectrum disorder. Translational Psychiatry, 2019, 9, 13.	2.4	28
90	A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling. Cell Chemical Biology, 2019, 26, 1143-1158.e6.	2.5	53

#	Article	IF	Citations
91	PTEN modulates gene transcription by redistributing genome-wide RNA polymerase II occupancy. Human Molecular Genetics, 2019, 28, 2826-2834.	1.4	8
92	The Microbiome of Temporal Arteries. Pathogens and Immunity, 2019, 4, 21.	1.4	19
93	Conformational Dynamics and Allosteric Regulation Landscapes of Germline PTEN Mutations Associated with Autism Compared to Those Associated with Cancer. American Journal of Human Genetics, 2019, 104, 861-878.	2.6	45
94	PTEN Mutations Trigger Resistance to Immunotherapy. Trends in Molecular Medicine, 2019, 25, 461-463.	3.5	20
95	BDNF and COMT, but not APOE, alleles are associated with psychiatric symptoms in refractory epilepsy. Epilepsy and Behavior, 2019, 94, 131-136.	0.9	9
96	Genome-wide tracts of homozygosity and exome analyses reveal repetitive elements with Barrets esophagus/esophageal adenocarcinoma risk. BMC Bioinformatics, 2019, 20, 98.	1.2	2
97	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. British Journal of Cancer, 2019, 121, 15-21.	2.9	101
98	Evolving indications and longâ€term oncological outcomes of riskâ€reducing bilateral nippleâ€sparing mastectomy. BJS Open, 2019, 3, 169-173.	0.7	18
99	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 213-220.	5.5	86
100	Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health. Pharmacological Reviews, 2019, 71, 1-19.	7.1	47
101	Dynamics and structural stability effects of germline PTEN mutations associated with cancer versus autism phenotypes. Journal of Biomolecular Structure and Dynamics, 2019, 37, 1766-1782.	2.0	37
102	PTEN-opathies: from biological insights to evidence-based precision medicine. Journal of Clinical Investigation, 2019, 129, 452-464.	3.9	128
103	Microbiome signature of bile from pancreatic and biliary tract cancer patients: A pilot study.. Journal of Clinical Oncology, 2019, 37, e15744-e15744.	0.8	2
104	Pro-tumorigenic non-pump function of sodium iodide symporter: A reimagined Trojan horse?. Oncotarget, 2019, 10, 688-689.	0.8	4
105	PTEN interacts with RNA polymerase II to dephosphorylate polymerase II C-terminal domain. Oncotarget, 2019, 10, 4951-4959.	0.8	8
106	Microbiomes of Inflammatory Thoracic Aortic Aneurysms Due to Giant Cell Arteritis and Clinically Isolated Aortitis Differ From Those of Non-Inflammatory Aneurysms. Pathogens and Immunity, 2019, 4, 105.	1.4	22
107	Germline EGFR mutation and cancer predisposition in adolescent and young adult (AYA) females with adrenocortical carcinoma.. Journal of Clinical Oncology, 2019, 37, e13014-e13014.	0.8	0
108	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 169, 561-571.	1.1	25

#	Article	IF	Citations
109	Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients. Journal of the American College of Surgeons, 2018, 226, 560-565.	0.2	19
110	Impact of an embedded genetic counselor on breast cancer treatment. Breast Cancer Research and Treatment, 2018, 169, 43-46.	1.1	35
111	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal of Epidemiology, 2018, 47, 987-997.	0.9	11
112	Patient Decisions to Receive Secondary Pharmacogenomic Findings and Development of a Multidisciplinary Practice Model to Integrate Results Into Patient Care. Clinical and Translational Science, 2018, 11, 71-76.	1.5	16
113	The microbiome in PTEN hamartoma tumor syndrome. Endocrine-Related Cancer, 2018, 25, 233-243.	1.6	5
114	KLLN-mediated DNA damage-induced apoptosis is associated with regulation of p53 phosphorylation and acetylation in breast cancer cells. Cell Death Discovery, 2018, 4, 31.	2.0	15
115	Geneâ€specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert Panel. Human Mutation, 2018, 39, 1581-1592.	1.1	123
116	ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and geneâ€level specification of the ACMG/AMP guidelines for sequence variant interpretation. Human Mutation, 2018, 39, 1614-1622.	1.1	132
117	A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling. Cancer Research, 2018, 78, 6121-6133.	0.4	25
118	Development and Validation of Objective and Quantitative Eye Trackingâ€'Based Measures of Autism Risk and Symptom Levels. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 858-866.	0.3	47
119	Hamartomatous Polyposis Syndromes. , 2018, , 165-183.		1
120	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 171, 421-426.	1.1	10
121	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocrine-Related Cancer, 2018, 25, T201-T219.	1.6	52
122	65 YEARS OF THE DOUBLE HELIX: One gene, many endocrine and metabolic syndromes: PTEN-opathies and precision medicine. Endocrine-Related Cancer, 2018, 25, T121-T140.	1.6	45
123	Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations. PLoS Genetics, 2018, 14, e1007352.	1.5	27
124	65 YEARS OF THE DOUBLE HELIX: Itâ€™s all in the DNA: understanding and managing endocrine neoplasms. Endocrine-Related Cancer, 2018, 25, E5-E7.	1.6	2
125	Preventive medicine of von Hippelâ€“Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	1.6	42
126	Non-canonical role of cancer-associated mutant SEC23B in the ribosome biogenesis pathway. Human Molecular Genetics, 2018, 27, 3154-3164.	1.4	6

#	Article	IF	Citations
127	Preliminary report: Late seizure recurrence years after epilepsy surgery may be associated with alterations in brain tissue transcriptome. Epilepsia Open, 2018, 3, 299-304.	1.3	11
128	Breast cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Research and Treatment, 2017, 165, 1-8.	1.1	78
129	Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas. Genome Medicine, 2017, 9, 14.	3.6	97
130	Thyroglobulin in Metastatic Thyroid Cancer: Culprit or Red Herring?. American Journal of Human Genetics, 2017, 100, 562-563.	2.6	1
131	A Meta-Analysis of Gaze Differences to Social and Nonsocial Information Between Individuals With and Without Autism. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 546-555.	0.3	211
132	A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children. Journal of Medical Genetics, 2017, 54, 471-478.	1.5	87
133	Clinical Implications for Germline PTEN Spectrum Disorders. Endocrinology and Metabolism Clinics of North America, 2017, 46, 503-517.	1.2	39
134	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. JAMA Oncology, 2017, 3, 1204.	3.4	149
135	Prevalence of HPV infection in racialâ€“ethnic subgroups of head and neck cancer patients. Carcinogenesis, 2017, 38, 218-229.	1.3	33
136	Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma. BBA Clinical, 2017, 7, 8-15.	4.1	24
137	Characterization of cryptic splicing in germline PTEN intronic variants in Cowden syndrome. Human Mutation, 2017, 38, 1372-1377.	1.1	34
138	The penetrance of MEN2 pheochromocytoma is not only determined by RET mutations. Endocrine-Related Cancer, 2017, 24, L63-L67.	1.6	19
139	Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory TÂcells. Journal of Allergy and Clinical Immunology, 2017, 139, 607-620.e15.	1.5	77
140	Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	160
141	Max Schottelius: Pioneer in Pheochromocytoma. Journal of the Endocrine Society, 2017, 1, 957-964.	0.1	14
142	Germline TTN variants are enriched in PTEN-wildtype Bannayanâ€“Rileyâ€“Ruvalcaba syndrome. Npj Genomic Medicine, 2017, 2, 37.	1.7	10
143	Cowden syndrome-associated germline succinate dehydrogenase complex subunit D (SDHD) variants cause PTEN-mediated down-regulation of autophagy in thyroid cancer cells. Human Molecular Genetics, 2017, 26, 1365-1375.	1.4	14
144	Bacteriome and mycobiome associations in oral tongue cancer. Oncotarget, 2017, 8, 97273-97289.	0.8	82

#	Article	IF	Citations
145	Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome. Annals of Translational Medicine, 2017, 5, 30-30.	0.7	45
146	Reply to G. Le Flahec et al. Journal of Clinical Oncology, 2017, 35, 377-377.	0.8	0
147	Immunotherapeutic target expression on breast tumors can be amplified by hormone receptor antagonism: a novel strategy for enhancing efficacy of targeted immunotherapy. Oncotarget, 2017, 8, 32536-32549.	0.8	10
148	Breast tissue, oral and urinary microbiomes in breast cancer. Oncotarget, 2017, 8, 88122-88138.	0.8	134
149	Varicella Zoster Virus and Large Vessel Vasculitis, the Absence of an Association. Pathogens and Immunity, 2017, 2, 228.	1.4	25
150	Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services. Pharmacotherapy, 2016, 36, 940-948.	1.2	102
151	Characterization of endolymphatic sac tumors and von Hippelâ€“Lindau disease in the International Endolymphatic Sac Tumor Registry. Head and Neck, 2016, 38, E673-9.	0.9	48
152	Germline compound heterozygous poly-glutamine deletion inUSF3may be involved in predisposition to heritable and sporadic epithelial thyroid carcinoma. Human Molecular Genetics, 2016, 26, ddw382.	1.4	14
153	Exome sequencing reveals germline gain-of-function EGFR mutation in an adult with Lhermitteâ€“Duclos disease. Journal of Physical Education and Sports Management, 2016, 2, a001230.	0.5	19
154	Cancer-predisposition geneKLLNmaintains pericentric H3K9 trimethylation protecting genomic stability. Nucleic Acids Research, 2016, 44, 3586-3594.	6.5	16
155	Analysis of Gut Microbiome Reveals Significant Differences between Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Controls. Journal of Urology, 2016, 196, 435-441.	0.2	79
156	Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. Journal of Clinical Oncology, 2016, 34, 2172-2181.	0.8	132
157	Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet. Npj Genomic Medicine, 2016, 1, 15006.	1.7	41
158	Assessment of clinical workload for general and specialty genetic counsellors at an academic medical center: a tool for evaluating genetic counselling practices. Npj Genomic Medicine, 2016, 1, 16010.	1.7	28
159	Mismatch Repair Deficiency in Colorectal Cancers: Is Somatic Genomic Testing the Grab-Bag for All Answers?. Journal of Clinical Oncology, 2016, 34, 2085-2087.	0.8	5
160	Neural transcriptome of constitutional Pten dysfunction in mice and its relevance to human idiopathic autism spectrum disorder. Molecular Psychiatry, 2016, 21, 118-125.	4.1	55
161	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a caseâ€“control study. Breast Cancer Research and Treatment, 2016, 155, 365-373.	1.1	55
162	HABP2in Familial Non-medullary Thyroid Cancer: Will the Real Mutation Please Stand Up?. Journal of the National Cancer Institute, 2016, 108, djw013.	3.0	14

#	Article	IF	Citations
163	Development of an Objective Autism Risk Index UsingÂRemote Eye Tracking. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 301-309.	0.3	57
164	The Urinary Microbiome Differs Significantly Between Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Controls as Well as Between Patients With Different Clinical Phenotypes. Urology, 2016, 92, 26-32.	0.5	106
165	Germline PARP4 mutations in patients with primary thyroid and breast cancers. Endocrine-Related Cancer, 2016, 23, 171-179.	1.6	39
166	Germline PTEN Mutation Analysis for PTEN Hamartoma Tumor Syndrome. Methods in Molecular Biology, 2016, 1388, 63-73.	0.4	9
167	Cytoplasm-predominant Pten associates with increased region-specific brain tyrosine hydroxylase and dopamine D2 receptors in mouse model with autistic traits. Molecular Autism, 2015, 6, 63.	2.6	16
168	Quantitative autism symptom patterns recapitulate differential mechanisms of genetic transmission in single and multiple incidence families. Molecular Autism, 2015, 6, 58.	2.6	25
169	Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutations. Pediatric Blood and Cancer, 2015, 62, 353-355.	0.8	4
170	PTEN hamartoma tumor syndrome. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 132, 129-137.	1.0	41
171	Selective roles of E2Fs for ErbB2- and Myc-mediated mammary tumorigenesis. Oncogene, 2015, 34, 119-128.	2.6	33
172	PTEN hamartoma tumor syndrome: Clinical risk assessment and management protocol. Methods, 2015, 77-78, 11-19.	1.9	51
173	KLLN epigenotypeâ€“phenotype associations in Cowden syndrome. European Journal of Human Genetics, 2015, 23, 1538-1543.	1.4	19
174	ACG Guidelines on Management of PTEN-Hamartoma Tumor Syndrome: Does the Evidence Support so Much so Young?. American Journal of Gastroenterology, 2015, 110, 1733-1734.	0.2	7
175	Missense mutation in the PTEN promoter of a patient with hemifacial hyperplasia. BoneKEy Reports, 2015, 4, 654.	2.7	6
176	Cowden syndrome-associated germline SDHD variants alter PTEN nuclear translocation through SRC-induced PTEN oxidation. Human Molecular Genetics, 2015, 24, 142-153.	1.4	25
177	Inflammatory disease of the aorta: Patterns and classification of giant cell aortitis, Takayasu arteritis, and nonsyndromic aortitis. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, S170-S175.	0.4	51
178	Pituitary Adenoma With Paraganglioma/Pheochromocytoma (3PAs) and Succinate Dehydrogenase Defects in Humans and Mice. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E710-E719.	1.8	121
179	Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer. Endocrine-Related Cancer, 2015, 22, 121-130.	1.6	30
180	New Genetic and Genomic Approaches After the Genome-wide Association Study Eraâ€"Back to the Future. Gastroenterology, 2015, 149, 1138-1141.	0.6	6

#	Article	IF	Citations
181	Association of specific PTEN/10q haplotypes with endometrial cancer phenotypes in African-American and European American women. Gynecologic Oncology, 2015, 138, 434-440.	0.6	9
182	Exome Sequencing Reveals Germline SMAD9 Mutation That Reduces Phosphatase and Tensin Homolog Expression and Is Associated With Hamartomatous Polyposis and Gastrointestinal Ganglioneuromas. Gastroenterology, 2015, 149, 886-889.e5.	0.6	24
183	Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis. Journal of Clinical Oncology, 2015, 33, 2537-2544.	0.8	16
184	Balancing Proliferation and Connectivity in PTEN-associated Autism Spectrum Disorder. Neurotherapeutics, 2015, 12, 609-619.	2.1	67
185	Communicating with Biobank Participants: Preferences for Receiving and Providing Updates to Researchers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 708-712.	1.1	13
186	Germline Heterozygous Variants in SEC23B Are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer. American Journal of Human Genetics, 2015, 97, 661-676.	2.6	76
187	RET Y791F Variant Does Not Increase the Risk for Medullary Thyroid Carcinoma. Thyroid, 2015, 25, 973-974.	2.4	6
188	Cowden syndrome: Recognizing and managing a notâ€soâ€rare hereditary cancer syndrome. Journal of Surgical Oncology, 2015, 111, 125-130.	0.8	106
189	Germline <scp>PTEN</scp>, <scp>SDHBâ€Ð</scp>, and <scp>KLLN</scp> alterations in endometrial cancer patients with Cowden and Cowdenâ€like syndromes: An international, multicenter, prospective study. Cancer, 2015, 121, 688-696.	2.0	46
190	Molecular and phenotypic abnormalities in individuals with germline heterozygous PTEN mutations and autism. Molecular Psychiatry, 2015, 20, 1132-1138.	4.1	132
191	Formative Evaluation of Clinician Experience with Integrating Family History-Based Clinical Decision Support into Clinical Practice. Journal of Personalized Medicine, 2014, 4, 115-136.	1.1	35
192	Germline Alterations in RASAL1 in Cowden Syndrome Patients Presenting with Follicular Thyroid Cancer and in Individuals with Apparently Sporadic Epithelial Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1316-E1321.	1.8	20
193	Glucocorticoid Receptor Î² Stimulates Akt1 Growth Pathway by Attenuation of PTEN. Journal of Biological Chemistry, 2014, 289, 17885-17894.	1.6	44
194	Equality in Lynch Syndrome Screening: Why Should We Hold Patients With Endometrial Cancer to a Different Standard?. Journal of Clinical Oncology, 2014, 32, 2277-2277.	0.8	10
195	Whole-genome sequencing: not yet making the clinical grade. Personalized Medicine, 2014, 11, 471-475.	0.8	0
196	BluepRINT for Moderate-to-Low Penetrance Cancer Susceptibility Genes Needed: Breast Cancer and Beyond. Cancer Discovery, 2014, 4, 762-763.	7.7	1
197	Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation. Molecular Cancer Therapeutics, 2014, 13, 517-527.	1.9	22
198	Pulmonary Arterial Hypertension in a Patient with Cowden Syndrome and the PTEN Mutation. Pulmonary Circulation, 2014, 4, 728-731.	0.8	6

#	Article	IF	Citations
199	A Unified Nomenclature and Amino Acid Numbering for Human PTEN. Science Signaling, 2014, 7, pe15.	1.6	50
200	Germline disruption of Pten localization causes enhanced sex-dependent social motivation and increased glial production. Human Molecular Genetics, 2014, 23, 3212-3227.	1.4	60
201	RE: Cowden Syndrome and PTEN Hamartoma Tumor Syndrome: Systematic Review and Revised Diagnostic Criteria. Journal of the National Cancer Institute, 2014, 106, dju130.	3.0	9
202	Increased Prevalence of Eosinophilic Gastrointestinal Disorders in Pediatric PTEN Hamartoma Tumor Syndromes. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 553-560.	0.9	41
203	Emergence, Involution, and Progression to Carcinoma of Mutant Clones in Normal Endometrial Tissues. Cancer Research, 2014, 74, 2796-2802.	0.4	48
204	Nuclear KLLN expression associates with improved relapse-free survival for prostate carcinoma. Endocrine-Related Cancer, 2014, 21, 579-586.	1.6	3
205	Biochemical screening and PTEN mutation analysis in individuals with autism spectrum disorders and macrocephaly. European Journal of Human Genetics, 2014, 22, 273-276.	1.4	72
206	A Practical Guide to Human Cancer Genetics. , 2014, , .		8
207	Second Malignant Neoplasms in Patients With Cowden Syndrome With Underlying Germline PTEN Mutations. Journal of Clinical Oncology, 2014, 32, 1818-1824.	0.8	105
208	A Twin Study of Heritable and Shared Environmental Contributions to Autism. Journal of Autism and Developmental Disorders, 2014, 44, 2013-2025.	1.7	95
209	TERT and BRAF in Thyroid Cancer: Teaming Up for Trouble. Journal of Clinical Oncology, 2014, 32, 2683-2684.	0.8	17
210	Exome Sequencing in Familial Colorectal Cancer: Searching for Needles in Haystacks. Gastroenterology, 2014, 147, 554-556.	0.6	1
211	Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncology, The, 2014, 15, 648-655.	5.1	137
212	Genetics of cognition in epilepsy. Epilepsy and Behavior, 2014, 41, 297-306.	0.9	20
213	How to spot heritable breast cancer: A primary care physicianâ€™s guide. Cleveland Clinic Journal of Medicine, 2014, 81, 31-40.	0.6	3
214	Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center. Gynecologic Oncology, 2013, 130, 121-126.	0.6	94
215	When Overgrowth Bumps Into Cancer: The PTEN-Opathies. , 2013, 163, n/a-n/a.		1
216	The development of a clinical screening tool for tumour predisposition syndromes in childhood cancer patients. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 52-52.	0.0	0

#	Article	IF	Citations
217	Transcription Factor KLLN Inhibits Tumor Growth byARSuppression, Induces Apoptosis byTP53/TP73Stimulation in Prostate Carcinomas, and Correlates With Cellular Differentiation. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E586-E594.	1.8	32
218	Brothers with germline PTEN mutations and persistent hypoglycemia, macrocephaly, developmental delay, short stature, and coagulopathy. Journal of Pediatric Endocrinology and Metabolism, 2013, 26, 137-41.	0.4	7
219	Germline PIK3CA and AKT1 Mutations in Cowden and Cowden-like Syndromes. American Journal of Human Genetics, 2013, 92, 76-80.	2.6	174
220	The development of a clinical screening instrument for tumour predisposition syndromes in childhood cancer patients. European Journal of Cancer, 2013, 49, 3247-3254.	1.3	18
221	When Overgrowth Bumps Into Cancer: The PTENâ€Opathies. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2013, 163, 114-121.	0.7	112
222	Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas. Human Molecular Genetics, 2013, 22, 2263-2272.	1.4	49
223	Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest. Human Molecular Genetics, 2013, 22, 2451-2461.	1.4	20
224	Implementation of Universal Microsatellite Instability and Immunohistochemistry Screening for Diagnosing Lynch Syndrome in a Large Academic Medical Center. Journal of Clinical Oncology, 2013, 31, 1336-1340.	0.8	147
225	A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma. Molecular Cancer Research, 2013, 11, 1061-1071.	1.5	135
226	The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Research and Treatment, 2013, 142, 177-185.	1.1	57
227	Renal cancer in von Hippelâ€“Lindau disease and related syndromes. Nature Reviews Nephrology, 2013, 9, 529-538.	4.1	55
228	Hunting for cancer in the microbial jungle. Genome Medicine, 2013, 5, 42.	3.6	1
229	Prevalence of Germline PTEN, BMPR1A, SMAD4, STK11, and ENG Mutations in Patients With Moderate-Load Colorectal Polyps. Gastroenterology, 2013, 144, 1402-1409.e5.	0.6	61
230	Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2013, 144, 956-966.e4.	0.6	216
231	Implementing genomic medicine in the clinic: the future is here. Genetics in Medicine, 2013, 15, 258-267.	1.1	472
232	International Rates of Breast Reconstruction After Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers. Annals of Surgical Oncology, 2013, 20, 3817-3822.	0.7	28
233	PTEN Germline Mutations in Patients Initially Tested for Other Hereditary Cancer Syndromes: Would Use of Risk Assessment Tools Reduce Genetic Testing?. Oncologist, 2013, 18, 1083-1090.	1.9	22
234	Cognitive characteristics of PTEN hamartoma tumor syndromes. Genetics in Medicine, 2013, 15, 548-553.	1.1	40

#	Article	IF	Citations
235	Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany. Nephrology Dialysis Transplantation, 2013, 28, 1472-1487.	0.4	81
236	RASAL1 in Thyroid Cancer: Wisdom From an Old Foe. Journal of the National Cancer Institute, 2013, 105, 1597-1599.	3.0	9
237	Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Research, 2013, 73, 3029-3040.	0.4	21
238	Population-Based Universal Screening for Lynch Syndrome: Ready, Setâ€¦ How?. Journal of Clinical Oncology, 2013, 31, 2527-2529.	0.8	12
239	Molecular genetics to genomic medicine practice: at the heart of valueâ€based delivery of healthcare. Molecular Genetics & Genomic Medicine, 2013, 1, 4-6.	0.6	7
240	Research Highlights: Highlights from the latest articles in personalized medicine. Personalized Medicine, 2013, 10, 231-233.	0.8	0
241	KLLN (killin, p53-regulated DNA replication inhibitor). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2013, , .	0.1	0
242	cgaTOH: Extended Approach for Identifying Tracts of Homozygosity. PLoS ONE, 2013, 8, e57772.	1.1	29
243	Into the eye of the storm: breast cancer's somatic mutation landscape points to DNA damage and repair. Translational Cancer Research, 2013, 2, 59-61.	0.4	1
244	Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endocrine-Related Cancer, 2012, 19, 283-290.	1.6	57
245	Vitamin E Protects against Lipid Peroxidation and Rescues Tumorigenic Phenotypes in Cowden/Cowden-like Patient-Derived Lymphoblast Cells with Germline SDHx Variants. Clinical Cancer Research, 2012, 18, 4954-4961.	3.2	22
246	Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1089-1096.	1.1	47
247	Obesity, diabetes mellitus, and cancer. Endocrine-Related Cancer, 2012, 19, E5-E7.	1.6	6
248	Utility of PTEN Protein Dosage in Predicting for Underlying GermlinePTENMutations among Patients Presenting with Thyroid Cancer and Cowden-Like Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2320-E2327.	1.8	17
249	Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers. European Journal of Human Genetics, 2012, 20, 547-551.	1.4	37
250	PTENmutations: help spot thyroid cancer before it occurs. Expert Review of Endocrinology and Metabolism, 2012, 7, 251-254.	1.2	1
251	GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Human Molecular Genetics, 2012, 21, 569-576.	1.4	52
252	Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma. Human Molecular Genetics, 2012, 21, 1557-1565.	1.4	55

#	Article	IF	Citations
253	Integrated Analysis Reveals Critical Genomic Regions in Prostate Tumor Microenvironment Associated with Clinicopathologic Phenotypes. Clinical Cancer Research, 2012, 18, 1578-1587.	3.2	34
254	Lifetime Cancer Risks of PTEN Mutation Carriersâ€"Response. Clinical Cancer Research, 2012, 18, 4214-4214.	3.2	0
255	Lifetime Cancer Risks in Individuals with Germline PTEN Mutations. Clinical Cancer Research, 2012, 18, 400-407.	3.2	738
256	Engaging basic scientists in translational research. Endocrine-Related Cancer, 2012, 19, E1-E3.	1.6	1
257	Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Human Molecular Genetics, 2012, 21, 300-310.	1.4	99
258	Thyroid cancer genetics: how close are we to personalizing clinical management?. Personalized Medicine, 2012, 9, 355-358.	0.8	1
259	PTEN Hamartoma of Soft Tissue. American Journal of Surgical Pathology, 2012, 36, 671-687.	2.1	95
260	The Prevalence of Hereditary Hemorrhagic Telangiectasia in Juvenile Polyposis Syndrome. Diseases of the Colon and Rectum, 2012, 55, 886-892.	0.7	71
261	A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines. Biological Procedures Online, 2012, 14, 5.	1.4	24
262	Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R42.	2.2	92
263	The clinical consequences of hemizygosity across 2ÂMB of 10q23 are restricted to Cowden syndrome. Breast Cancer Research and Treatment, 2012, 136, 911-918.	1.1	0
264	Papillary Renal Cell Carcinoma Is Associated With PTEN Hamartoma Tumor Syndrome. Urology, 2012, 79, 1187.e1-1187.e7.	0.5	63
265	Characterization of the colorectal cancerâ€"associated enhancer MYC-335 at 8q24: the role of rs67491583. Cancer Genetics, 2012, 205, 25-33.	0.2	24
266	Engaging basic scientists in translational research: identifying opportunities, overcoming obstacles. Journal of Translational Medicine, 2012, 10, 72.	1.8	43
267	Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genetics in Medicine, 2012, 14, 819-822.	1.1	78
268	PTEN Lipid Phosphatase Activity and Proper Subcellular Localization Are Necessary and Sufficient for Down-Regulating AKT Phosphorylation in the Nucleus in Cowden Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2179-E2187.	1.8	18
269	Elevated plasma succinate in PTEN, SDHB, and SDHD mutationâ€"positive individuals. Genetics in Medicine, 2012, 14, 616-619.	1.1	41
270	Autoimmunity, Intestinal Lymphoid Hyperplasia, and Defects in Mucosal B-Cell Homeostasis in Patients With PTEN Hamartoma Tumor Syndrome. Gastroenterology, 2012, 142, 1093-1096.e6.	0.6	61

#	Article	IF	Citations
271	Should patients with Cowden syndrome undergo prophylactic thyroidectomy?. Surgery, 2012, 152, 1201-1210.	1.0	54
272	Validation of Proposed DSM-5 Criteria for Autism Spectrum Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51, 28-40.e3.	0.3	287
273	Integrative Genomic Analysis Reveals Extended Germline Homozygosity with Lung Cancer Risk in the PLCO Cohort. PLoS ONE, 2012, 7, e31975.	1.1	13
274	Chromosome 3 Status in Uveal Melanoma: A Comparison of Fluorescence In Situ Hybridization and Single-Nucleotide Polymorphism Array. , 2012, 53, 3331.		35
275	Personalised care and the genome. BMJ, The, 2012, 344, e3174-e3174.	3.0	9
276	PTEN hamartoma tumor syndrome and Gorhamâ€“Stout phenomenon. American Journal of Medical Genetics, Part A, 2012, 158A, 1719-1723.	0.7	17
277	Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Research and Treatment, 2012, 131, 849-858.	1.1	45
278	Building an innovative model for personalized healthcare. Cleveland Clinic Journal of Medicine, 2012, 79, S1-S9.	0.6	15
279	Personalizing patient care. Cleveland Clinic Journal of Medicine, 2012, 79, 329-330.	0.6	0
280	Frequency of Germline PTEN Mutations in Differentiated Thyroid Cancer. Thyroid, 2011, 21, 505-510.	2.4	56
281	Multiple endocrine neoplasia type 2: An overview. Genetics in Medicine, 2011, 13, 755-764.	1.1	161
282	Circulating tumor cells in uveal melanoma. Future Oncology, 2011, 7, 101-109.	1.1	30
283	Testicular microlithiasis: recent advances in understanding and management. Nature Reviews Urology, 2011, 8, 153-163.	1.9	36
284	Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Letters, 2011, 301, 168-176.	3.2	104
285	Evil lurks in the heart of man: cardiac paraganglioma presenting as recurrent dyspnoea and chronic cough. BMJ Case Reports, 2011, 2011, bcr1120115170-bcr1120115170.	0.2	5
286	Adenomatoid tumour of the adrenal gland in a patient with germline SDHD mutation: a case report and review of the literature. Pathology, 2011, 43, 495-498.	0.3	9
287	Addressing gaps in physician education using personal genomic testing. Genetics in Medicine, 2011, 13, 750-751.	1.1	23
288	Defining Phenotypes and Cancer Risk in Hyperplastic Polyposis Syndrome. Diseases of the Colon and Rectum, 2011, 54, 164-170.	0.7	114

#	Article	IF	Citations
289	Germline Mutations in MSR1, ASCC1, and CTHRC1 in Patients With Barrett Esophagus and Esophageal Adenocarcinoma. JAMA - Journal of the American Medical Association, 2011, 306, 410.	3.8	96
290	A large health system's approach to utilization of the genetic counselor CPTÂ® 96040 code. Genetics in Medicine, 2011, 13, 1011-1014.	1.1	21
291	Age-Related Penetrance of Hereditary Atypical Hemolytic Uremic Syndrome. Annals of Human Genetics, 2011, 75, 639-647.	0.3	29
292	Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene, 2011, 30, 4327-4338.	2.6	85
293	Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. European Journal of Human Genetics, 2011, 19, 763-768.	1.4	93
294	Microenvironmental genomic alterations reveal signaling networks for head and neck squamous cell carcinoma. Journal of Clinical Bioinformatics, 2011, 1, 21.	1.2	5
295	A Clinical Scoring System for Selection of Patients for PTEN Mutation Testing Is Proposed on the Basis of a Prospective Study of 3042 Probands. American Journal of Human Genetics, 2011, 88, 42-56.	2.6	332
296	Response to Bayley: Functional Study Informs Bioinformatic Analysis. American Journal of Human Genetics, 2011, 88, 676.	2.6	3
297	Laparoscopic Organâ€Sparing Resection of Von Hippelâ€Lindau Diseaseâ€Associated Pancreatic Neuroendocrine Tumors. World Journal of Surgery, 2011, 35, 563-567.	0.8	6
298	Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes and Cancer, 2011, 50, 654-661.	1.5	33
299	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Human Mutation, 2011, 32, 51-58.	1.1	117
300	Germline Mutations of the TMEM127 Gene in Patients with Paraganglioma of Head and Neck and Extraadrenal Abdominal Sites. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1279-E1282.	1.8	91
301	Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53. Human Molecular Genetics, 2011, 20, 80-89.	1.4	31
302	Incidence and Clinical Characteristics of Thyroid Cancer in Prospective Series of Individuals with Cowden and Cowden-Like Syndrome Characterized by Germline PTEN, SDH, or KLLN Alterations. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E2063-E2071.	1.8	172
303	Upper and Lower Gastrointestinal Findings in PTEN Mutationâ€“Positive Cowden Syndrome Patients Participating in an Active Surveillance Program. Clinical and Translational Gastroenterology, 2011, 2, e5.	1.3	51
304	HPV statusâ€independent association of alcohol and tobacco exposure or prior radiation therapy with promoter methylation of FUSSEL18, EBF3, IRX1, and SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas. Genes Chromosomes and Cancer, 2010, 49, 319-326.	1.5	42
305	Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Research and Treatment, 2010, 123, 661-677.	1.1	86
306	Head circumference in the clinical detection of PTEN hamartoma tumor syndrome in a clinic population at high-risk of breast cancer. Breast Cancer Research and Treatment, 2010, 124, 459-465.	1.1	11

#	Article	IF	Citations
307	Lhermitte-Duclos disease caused by a novel germlinePTENmutation R173P in a patient presenting with psychosis. Neuropathology and Applied Neurobiology, 2010, 36, 86-89.	1.8	5
308	Mendelian genetics of rareâ€"and not so rareâ€"cancers. Annals of the New York Academy of Sciences, 2010, 1214, 70-82.	1.8	32
309	Bioethical and Clinical Dilemmas of Direct-to-Consumer Personal Genomic Testing: The Problem of Misattributed Equivalence. Science Translational Medicine, 2010, 2, 17cm5.	5.8	34
310	Allele-specific tumor spectrum in Pten knockin mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5142-5147.	3.3	59
311	Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Human Molecular Genetics, 2010, 19, 4319-4329.	1.4	85
312	Autism Spectrum Disorders as a Qualitatively Distinct Category From Typical Behavior in a Large, Clinically Ascertained Sample. Assessment, 2010, 17, 308-320.	1.9	69
313	Germline Epigenetic Regulation of <emph type="ital">KILLIN</emph> in Cowden and Cowden-like Syndrome. JAMA - Journal of the American Medical Association, 2010, 304, 2724.	3.8	138
314	Pathogenicity of DNA Variants and Double Mutations in Multiple Endocrine Neoplasia Type 2 and Von Hippel-Lindau Syndrome. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 308-313.	1.8	73
315	Systematic comparison of sporadic and syndromic pancreatic islet cell tumors. Endocrine-Related Cancer, 2010, 17, 875-883.	1.6	29
316	Frequent Gastrointestinal Polyps and Colorectal Adenocarcinomas in a Prospective Series of PTEN Mutation Carriers. Gastroenterology, 2010, 139, 1927-1933.	0.6	251
317	Common alleles of predisposition in endocrine neoplasia. Current Opinion in Genetics and Development, 2010, 20, 251-256.	1.5	7
318	Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma. American Journal of Pathology, 2010, 176, 3062-3072.	1.9	65
319	Linkage Disequilibrium between Two High-Frequency Deletion Polymorphisms: Implications for Association Studies Involving the glutathione-S transferase (GST) Genes. PLoS Genetics, 2009, 5, e1000472.	1.5	44
320	AP-2Î± Induces Epigenetic Silencing of Tumor Suppressive Genes and Microsatellite Instability in Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2009, 4, e6931.	1.1	18
321	Disruption of Transforming Growth Factor-Î² Signaling by Five Frequently Methylated Genes Leads to Head and Neck Squamous Cell Carcinoma Pathogenesis. Cancer Research, 2009, 69, 9301-9305.	0.4	30
322	Activation of the PI3K/AKT Pathway Induces Urothelial Carcinoma of the Renal Pelvis: Identification in Human Tumors and Confirmation in Animal Models. Cancer Research, 2009, 69, 8256-8264.	0.4	60
323	Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function. Human Molecular Genetics, 2009, 18, 2851-2862.	1.4	41
324	Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients. Clinical Cancer Research, 2009, 15, 6378-6385.	3.2	160

#	Article	IF	Citations
325	Gene Expression Profiling Identifies MMP-12 and ADAMDEC1 as Potential Pathogenic Mediators of Pulmonary Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 929-938.	2.5	127
326	Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1938-1944.	1.8	112
327	A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas. Clinical Cancer Research, 2009, 15, 5895-5901.	3.2	101
328	Genomic Alterations in Tumor Stroma. Cancer Research, 2009, 69, 6759-6764.	0.4	51
329	The Approach to the Patient with Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2677-2683.	1.8	77
330	Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out. Cancer Research, 2009, 69, 3650-3656.	0.4	178
331	Familial hyperparathyroidism: Surgical outcome after 30 years of follow-up in 3 families with germline HRPT2 mutations. Surgery, 2009, 145, 249-250.	1.0	1
332	Activator protein 2 alpha (AP2Î±) suppresses 42 kDa C/CAAT enhancer binding protein Î± (p42^{C/EBPÎ±}) in head and neck squamous cell carcinoma. International Journal of Cancer, 2009, 124, 1285-1292.	2.3	14
333	Squamous morules are functionally inert elements of premalignant endometrial neoplasia. Modern Pathology, 2009, 22, 167-174.	2.9	57
334	PTEN hamartoma tumor syndrome: An overview. Genetics in Medicine, 2009, 11, 687-694.	1.1	311
335	Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association. Thyroid, 2009, 19, 565-612.	2.4	1,247
336	Cost-effective method for growing three-dimensional cell cultures in extracellular matrix extract. Biotechnic and Histochemistry, 2009, 84, 25-28.	0.7	0
337	Nuclear PTEN levels and G2 progression in melanoma cells. Melanoma Research, 2009, 19, 203-210.	0.6	13
338	A practical guide to interpretation and clinical application of personal genomic screening. BMJ: British Medical Journal, 2009, 339, b4253-b4253.	2.4	20
339	Familial risk for soft tissue tumors: a nation-wide epidemiological study from Sweden. Journal of Cancer Research and Clinical Oncology, 2008, 134, 617-624.	1.2	16
340	BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia. American Journal of Medical Genetics, Part A, 2008, 146A, 2551-2556.	0.7	43
341	Germline Mutations and Variants in the Succinate Dehydrogenase Genes in Cowden and Cowden-like Syndromes. American Journal of Human Genetics, 2008, 83, 261-268.	2.6	205
342	A ringleader identified. Nature, 2008, 455, 883-884.	13.7	12

#	Article	IF	Citations
343	Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene, 2008, 27, 5387-5397.	2.6	131
344	Clinical and molecular genetics of patients with the Carneyâ€“Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. European Journal of Human Genetics, 2008, 16, 79-88.	1.4	446
345	Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer. Cancer Genetics and Cytogenetics, 2008, 183, 83-88.	1.0	30
346	Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery, 2008, 143, 630-640.	1.0	52
347	SNP Arrays in Heterogeneous Tissue: Highly Accurate Collection of Both Germline and Somatic Genetic Information from Unpaired Single Tumor Samples. American Journal of Human Genetics, 2008, 82, 903-915.	2.6	47
348	Differential Expression of PTEN-Targeting MicroRNAs miR-19a and miR-21 in Cowden Syndrome. American Journal of Human Genetics, 2008, 82, 1141-1149.	2.6	97
349	Targeted therapy for uveal melanoma. Cancer Treatment Reviews, 2008, 34, 247-258.	3.4	90
350	ATP modulates PTEN subcellular localization in multiple cancer cell lines. Human Molecular Genetics, 2008, 17, 2877-2885.	1.4	32
351	Germline Genomic Homozygosity and Cancer Riskâ€”Reply. JAMA - Journal of the American Medical Association, 2008, 300, 169.	3.8	0
352	Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Annals of Oncology, 2008, 19, 1903-1909.	0.6	31
353	Unregulated smooth-muscle myosin in human intestinal neoplasia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5513-5518.	3.3	77
354	SDHB--A Gene for All Tumors?. Journal of the National Cancer Institute, 2008, 100, 1193-1195.	3.0	16
355	Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. Endocrine-Related Cancer, 2008, 15, 1035-1041.	1.6	45
356	The nuclear affairs of PTEN. Journal of Cell Science, 2008, 121, 249-253.	1.2	259
357	Direct Evidence for Epithelial-Mesenchymal Transitions in Breast Cancer. Cancer Research, 2008, 68, 937-945.	0.4	329
358	Frequency of Germline Genomic Homozygosity Associated With Cancer Cases. JAMA - Journal of the American Medical Association, 2008, 299, 1437.	3.8	46
359	Multiple Tumors in a Child with Germ-Line Mutations inTP53andPTEN. New England Journal of Medicine, 2008, 359, 537-539.	13.9	20
360	Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 111-115.	2.9	95

#	Article	IF	Citations
361	Impact of Screening Kindreds for SDHD p.Cys11X as a Common Mutation Associated with Paraganglioma Syndrome Type 1. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4818-4825.	1.8	28
362	Microenvironmental Protection in Diffuse Large-B-Cell Lymphoma. New England Journal of Medicine, 2008, 359, 2379-2381.	13.9	8
363	Update on the Molecular Diagnosis of Endocrine Tumors: Toward â€“omics-Based Personalized Healthcare?. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1097-1104.	1.8	17
364	Interview. Personalized Medicine, 2008, 5, 569-573.	0.8	0
365	First Report of Ovarian Dysgerminoma in Cowden Syndrome with Germline PTEN Mutation and PTEN-related 10q Loss of Tumor Heterozygosity. American Journal of Surgical Pathology, 2008, 32, 1258-1264.	2.1	23
366	Pilot Study of Rosiglitazone Therapy in Women with Breast Cancer: Effects of Short-term Therapy on Tumor Tissue and Serum Markers. Clinical Cancer Research, 2007, 13, 246-252.	3.2	82
367	Familial adenomatous polyposis in a patient with unexplained mental retardation. Nature Clinical Practice Neurology, 2007, 3, 694-700.	2.7	29
368	Germline mutations in PTEN and SDHC in a woman with epithelial thyroid cancer and carotid paraganglioma. Nature Clinical Practice Oncology, 2007, 4, 608-612.	4.3	28
369	Breast-Cancer Stromal Cells withTP53Mutations and Nodal Metastases. New England Journal of Medicine, 2007, 357, 2543-2551.	13.9	288
370	Molecular characterisation of a common SDHB deletion in paraganglioma patients. Journal of Medical Genetics, 2007, 45, 233-238.	1.5	69
371	Microenvironmental Genomic Alterations and Clinicopathological Behavior in Head and Neck Squamous Cell Carcinoma. JAMA - Journal of the American Medical Association, 2007, 297, 187.	3.8	100
372	Genomic Instability Within Tumor Stroma and Clinicopathological Characteristics of Sporadic Primary Invasive Breast Carcinoma. JAMA - Journal of the American Medical Association, 2007, 297, 2103.	3.8	101
373	Genetics of Carney Triad: Recurrent Losses at Chromosome 1 but Lack of Germline Mutations in Genes Associated with Paragangliomas and Gastrointestinal Stromal Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2938-2943.	1.8	141
374	Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome. Nature Clinical Practice Oncology, 2007, 4, 433-438.	4.3	29
375	GermlineNF1Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792.	1.8	126
376	PTEN regulates phospholipase D and phospholipase C. Human Molecular Genetics, 2007, 16, 1157-1163.	1.4	17
377	Comparative genomic and functional analyses reveal a novel cis-acting PTEN regulatory element as a highly conserved functional E-box motif deleted in Cowden syndrome. Human Molecular Genetics, 2007, 16, 1058-1071.	1.4	48
378	Evidence of MEN-2 in the Original Description of Classic Pheochromocytoma. New England Journal of Medicine, 2007, 357, 1311-1315.	13.9	95

#	Article	IF	Citations
379	Regulation of the PTEN promoter by statins and SREBP. Human Molecular Genetics, 2007, 17, 919-928.	1.4	34
380	Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein Î± Is Epigenetically Down-regulated in Head and Neck Squamous Cell Carcinoma. Cancer Research, 2007, 67, 4657-4664.	0.4	76
381	Loss of Expression of Protein Kinase A Regulatory Subunit 1Î± in Pigmented Epithelioid Melanocytoma But Not in Melanoma or Other Melanocytic Lesions. American Journal of Surgical Pathology, 2007, 31, 1764-1775.	2.1	115
382	Long-term Outcome in a Patient With Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia. Chest, 2007, 131, 984-987.	0.4	16
383	Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity. Cell, 2007, 128, 157-170.	13.5	879
384	Cowden Syndromeâ€“Affected Patients with PTEN Promoter Mutations Demonstrate Abnormal Protein Translation. American Journal of Human Genetics, 2007, 81, 756-767.	2.6	75
385	Consortium approach to identifying genes for Barrettâ€™s esophagus and esophageal adenocarcinoma. Translational Research, 2007, 150, 3-17.	2.2	14
386	Hamartomatous polyposis syndromes. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 492-502.	1.7	204
387	A novelPTEN mutation in Cowden syndrome is associated with a mixed degenerative-erosive arthritic process: Potential molecular pathogenic mechanisms. American Journal of Medical Genetics, Part A, 2007, 143A, 1522-1527.	0.7	3
388	Cancer phenomics: RET and PTEN as illustrative models. Nature Reviews Cancer, 2007, 7, 35-45.	12.8	231
389	Heritable clustering and pathway discovery in breast cancer integrating epigenetic and phenotypic data. BMC Bioinformatics, 2007, 8, 38.	1.2	18
390	Cowden Syndrome. Seminars in Oncology, 2007, 34, 428-434.	0.8	135
391	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2007, 105, 221-228.	1.1	45
392	Spontaneous and therapeutic abortions and the risk of breast cancer among BRCAmutation carriers. Breast Cancer Research, 2006, 8, R15.	2.2	44
393	Total-Genome Analysis of BRCA1/2-Related Invasive Carcinomas of the Breast Identifies Tumor Stroma as Potential Landscaper for Neoplastic Initiation. American Journal of Human Genetics, 2006, 78, 961-972.	2.6	84
394	Distinct Expression Profiles for PTEN Transcript and Its Splice Variants in Cowden Syndrome and Bannayan-Riley-Ruvalcaba Syndrome. American Journal of Human Genetics, 2006, 79, 23-30.	2.6	43
395	Reply to Salviati et al.. American Journal of Human Genetics, 2006, 79, 596-597.	2.6	11
396	Mutation-Positive and Mutation-Negative Patients with Cowden and Bannayan-Riley-Ruvalcaba Syndromes Associated with Distinct 10q Haplotypes. American Journal of Human Genetics, 2006, 79, 923-934.	2.6	30

#	Article	IF	Citations
397	Contiguous Gene Deletion within Chromosome Arm 10q Is Associated with Juvenile Polyposis of Infancy, Reflecting Cooperation between the BMPR1A and PTEN Tumor-Suppressor Genes. American Journal of Human Genetics, 2006, 78, 1066-1074.	2.6	127
398	Two-dimensional gel proteome reference map of blood monocytes. Proteome Science, 2006, 4, 16.	0.7	20
399	PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent Manner. Cancer Research, 2006, 66, 736-742.	0.4	99
400	Functioning Paraganglioma and Gastrointestinal Stromal Tumor of the Jejunum in Three Women. American Journal of Surgical Pathology, 2006, 30, 42-49.	2.1	34
401	Thymic carcinoid in multiple endocrine neoplasia 1: genotype-phenotype correlation and prevention. Journal of Internal Medicine, 2006, 259, 428-432.	2.7	33
402	Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Human Molecular Genetics, 2006, 15, 777-787.	1.4	64
403	Genetic and Clinical Investigation of Pheochromocytoma: A 22-Year Experience, from Freiburg, Germany to International Effort. Annals of the New York Academy of Sciences, 2006, 1073, 122-137.	1.8	15
404	EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis. BMC Cancer, 2006, 6, 145.	1.1	19
405	A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer, 2006, 6, 278.	1.1	46
406	Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer, 2006, 107, 2160-2166.	2.0	87
407	Coffee consumption and breast cancer risk amongBRCA1 andBRCA2 mutation carriers. International Journal of Cancer, 2006, 118, 103-107.	2.3	73
408	Increased PTEN expression due to transcriptional activation of PPARÎ³ by Lovastatin and Rosiglitazone. International Journal of Cancer, 2006, 118, 2390-2398.	2.3	108
409	A germlinePTEN mutation with manifestations of prenatal onset and verrucous epidermal nevus. American Journal of Medical Genetics, Part A, 2006, 140A, 1472-1475.	0.7	12
410	The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Human Molecular Genetics, 2006, 15, 2553-2559.	1.4	106
411	Comprehensive Mutation Scanning of NF1 in Apparently Sporadic Cases of Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3478-3481.	1.8	53
412	High Frequency of Loss of Heterozygosity in Imprinted, Compared with Nonimprinted, Genomic Regions in Follicular Thyroid Carcinomas and Atypical Adenomas. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 262-269.	1.8	22
413	Nuclear Localization of PTEN Is Regulated by Ca2+ through a Tyrosil Phosphorylationâ€“Independent Conformational Modification in Major Vault Protein. Cancer Research, 2006, 66, 11677-11682.	0.4	74
414	Familiality in Barrett's Esophagus, Adenocarcinoma of the Esophagus, and Adenocarcinoma of the Gastroesophageal Junction. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1668-1673.	1.1	104

#	Article	IF	Citations
415	CASE 4. Fibrocystic Breast Disease in a 16-Year-Old Female With PTEN Hamartoma Tumor Syndrome. Journal of Clinical Oncology, 2006, 24, 525-527.	0.8	2
416	Mapping Geographic Zones of Cancer Risk with Epigenetic Biomarkers in Normal Breast Tissue. Clinical Cancer Research, 2006, 12, 6626-6636.	3.2	201
417	A Limited Set of Human MicroRNA Is Deregulated in Follicular Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3584-3591.	1.8	285
418	A complex additive model of inheritance for Hirschsprung disease is supported by both RET mutations and predisposing RET haplotypes. Genetics in Medicine, 2006, 8, 704-710.	1.1	29
419	High Frequency of Submicroscopic Hemizygous Deletion Is a Major Mechanism of Loss of Expression of PTEN in Uveal Melanoma. Journal of Clinical Oncology, 2006, 24, 288-295.	0.8	110
420	p53 Down-Regulates Phosphatase and Tensin Homologue Deleted on Chromosome 10 Protein Stability Partially through Caspase-Mediated Degradation in Cells with Proteasome Dysfunction. Cancer Research, 2006, 66, 6139-6148.	0.4	53
421	Pheochromocytoma â€“ where are we? Where should we go? A medical and scientific odyssey. Familial Cancer, 2005, 4, 1-1.	0.9	0
422	Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN) Has Nuclear Localization Signalâ€“Like Sequences for Nuclear Import Mediated by Major Vault Protein. Cancer Research, 2005, 65, 4108-4116.	0.4	142
423	Phytoestrogen exposure elevates PTEN levels. Human Molecular Genetics, 2005, 14, 1457-1463.	1.4	72
424	Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the <EMPH TYPE="ITAL">SDHC</EMPH> Gene. JAMA - Journal of the American Medical Association, 2005, 294, 2057.	3.8	309
425	Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN. Human Molecular Genetics, 2005, 14, 2459-2468.	1.4	33
426	Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting. Journal of Clinical Oncology, 2005, 23, 5847-5848.	0.8	8
427	Ancestral RET haplotype associated with Hirschsprung's disease shows linkage disequilibrium breakpoint at -1249. Journal of Medical Genetics, 2005, 42, 322-327.	1.5	26
428	Silencing of the Maternally Imprinted Tumor Suppressor ARHI Contributes to Follicular Thyroid Carcinogenesis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1149-1155.	1.8	52
429	Genetic Classification of Benign and Malignant Thyroid Follicular Neoplasia Based on a Three-Gene Combination. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2512-2521.	1.8	152
430	Gene-expression profiling in differentiated thyroid cancer â€“ a viable strategy for the practice of genomic medicine?. Future Oncology, 2005, 1, 497-510.	1.1	19
431	Editorial: Germline Variants within RET: Clinical Utility or Scientific Playtoy?. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6334-6336.	1.8	22
432	Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. British Journal of Cancer, 2005, 92, 1922-1926.	2.9	65

#	Article	IF	Citations
433	Variable Expression of Coxsackie-Adenovirus Receptor in Thyroid Tumors: Implications for Adenoviral Gene Therapy. Thyroid, 2005, 15, 977-987.	2.4	13
434	Nuclear-Cytoplasmic Partitioning of Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN) Differentially Regulates the Cell Cycle and Apoptosis. Cancer Research, 2005, 65, 8096-8100.	0.4	177
435	Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis. JAMA - Journal of the American Medical Association, 2005, 294, 2465.	3.8	218
436	Serendipity, fate, science and leadership. Cancer Biology and Therapy, 2005, 4, 1422-1425.	1.5	1
437	Penetrance and Clinical Manifestations of Non-Hotspot Germline RET Mutation, C630R, in a Family with Medullary Thyroid Carcinoma. Thyroid, 2005, 15, 668-671.	2.4	12
438	Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. Journal of Medical Genetics, 2005, 42, 318-321.	1.5	673
439	Familial Risks for Nonmedullary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5747-5753.	1.8	151
440	High Frequency of Large Gene Deletions and Rearrangements in Lynch Syndromeâ€“Back to the Future?. Gastroenterology, 2005, 129, 1124-1126.	0.6	0
441	Cancer Characteristics in Swedish Families Fulfilling Criteria for Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology, 2005, 129, 1889-1899.	0.6	41
442	Decision Aids From Genetics to Treatment of Breast Cancer. JAMA - Journal of the American Medical Association, 2004, 292, 496.	3.8	7
443	The RET IVS1-126G>T Variant Is Strongly Associated with the Development of Sporadic Medullary Thyroid Cancer. Thyroid, 2004, 14, 329-331.	2.4	16
444	Combined Total Genome Loss of Heterozygosity Scan of Breast Cancer Stroma and Epithelium Reveals Multiplicity of Stromal Targets. Cancer Research, 2004, 64, 7231-7236.	0.4	143
445	Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. Journal of Medical Genetics, 2004, 41, 801-807.	1.5	45
446	Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. Journal of Medical Genetics, 2004, 41, 323-326.	1.5	282
447	Distinct Clinical Features of Paraganglioma Syndromes Associated With <EMPH TYPE="ITAL">SDHB</EMPH> and <EMPH TYPE="ITAL">SDHD</EMPH> Gene Mutations. JAMA - Journal of the American Medical Association, 2004, 292, 943.	3.8	821
448	Large Germline Deletions of Mitochondrial Complex II Subunits SDHB and SDHD in Hereditary Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5694-5699.	1.8	81
449	PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene, 2004, 23, 617-628.	2.6	135
450	Highly penetrant hereditary cancer syndromes. Oncogene, 2004, 23, 6445-6470.	2.6	302

#	Article	IF	Citations
451	Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. British Journal of Cancer, 2004, 91, 1835-1841.	2.9	43
452	Papillary and Follicular Thyroid Carcinomas Show Distinctly Different Microarray Expression Profiles and Can Be Distinguished by a Minimum of Five Genes. Journal of Clinical Oncology, 2004, 22, 3531-3539.	0.8	137
453	Early-Onset Renal Cell Carcinoma as a Novel Extraparaganglial Component of SDHB-Associated Heritable Paraganglioma. American Journal of Human Genetics, 2004, 74, 153-159.	2.6	367
454	PTEN: One Gene, Many Syndromes. Human Mutation, 2003, 22, 183-198.	1.1	729
455	TheRETC620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes. Human Mutation, 2003, 22, 412-415.	1.1	9
456	Constipation, polyps, or cancer? letPTEN predict your future. American Journal of Medical Genetics Part A, 2003, 122A, 315-322.	2.4	29
457	Genetic analysis of mitochondrial complex II subunits SDHD , SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clinical Endocrinology, 2003, 59, 728-733.	1.2	97
458	Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene, 2003, 22, 3412-3416.	2.6	61
459	Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene, 2003, 22, 4611-4616.	2.6	125
460	A role for mitochondrial enzymes in inherited neoplasia and beyond. Nature Reviews Cancer, 2003, 3, 193-202.	12.8	359
461	From developmental disorder to heritable cancer: it's all in the BMP/TGF-Î² family. Nature Reviews Genetics, 2003, 4, 763-773.	7.7	258
462	A Founding Locus within the RET Proto-Oncogene May Account for a Large Proportion of Apparently Sporadic Hirschsprung Disease and a Subset of Cases of Sporadic Medullary Thyroid Carcinoma. American Journal of Human Genetics, 2003, 72, 88-100.	2.6	100
463	An Ancestral Ashkenazi Haplotype at the HMPS/CRAC1 Locus on 15q13â€“q14 Is Associated with Hereditary Mixed Polyposis Syndrome. American Journal of Human Genetics, 2003, 72, 1261-1267.	2.6	98
464	Germline PTEN Promoter Mutations and Deletions in Cowden/Bannayan-Riley-Ruvalcaba Syndrome Result in Aberrant PTEN Protein and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway. American Journal of Human Genetics, 2003, 73, 404-411.	2.6	283
465	Germline Inactivation of PTEN and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway Cause Human Lhermitte-Duclos Disease in Adults. American Journal of Human Genetics, 2003, 73, 1191-1198.	2.6	213
466	PTEN hamartoma tumour syndrome: variability of an entity. Journal of Medical Genetics, 2003, 40, 111e-111.	1.5	56
467	De novo germline PTEN mutation in a man with Lhermitte-Duclos disease which arose on the paternal chromosome and was transmitted to his child with polydactyly and Wormian bones. Journal of Medical Genetics, 2003, 40, 92e-92.	1.5	18
468	BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Human Molecular Genetics, 2003, 12, 679-684.	1.4	103

#	Article	IF	Citations
469	PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway. Human Molecular Genetics, 2003, 12, 1943-1943.	1.4	1
470	Gi Polyposis and Glycogenic Acanthosis of The Esophagus Associated With Pten Mutation Positive Cowden Syndrome in The Absence of Cutaneous Manifestations. American Journal of Gastroenterology, 2003, 98, 1429-1434.	0.2	75
471	Peroxisome Proliferator-activated Receptor Î³-mediated Differentiation. Journal of Biological Chemistry, 2003, 278, 22669-22677.	1.6	48
472	Intronic Single Nucleotide Polymorphisms in theRETProtooncogene Are Associated with a Subset of Apparently Sporadic Pheochromocytoma and May Modulate Age of Onset. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4911-4916.	1.8	26
473	Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Research, 2003, 63, 282-6.	0.4	94
474	Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Research, 2003, 63, 2864-71.	0.4	71
475	APC-dependent suppression of colon carcinogenesis by PPARÂ. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13771-13776.	3.3	252
476	Protein-Kinase A and Human Disease: The Core of cAMP-Dependent Signaling in Health and Disease. Hormone and Metabolic Research, 2002, 34, 169-175.	0.7	3
477	The pressure rises: update on the genetics of phaeochromocytoma. Human Molecular Genetics, 2002, 11, 2347-2354.	1.4	154
478	Germ-Line Mutations in Nonsyndromic Pheochromocytoma. New England Journal of Medicine, 2002, 346, 1459-1466.	13.9	1,299
479	PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway. Human Molecular Genetics, 2002, 11, 1687-1696.	1.4	70
480	PTEN Mutational Spectra, Expression Levels, and Subcellular Localization in Microsatellite Stable and Unstable Colorectal Cancers. American Journal of Pathology, 2002, 161, 439-447.	1.9	173
481	Protean PTEN: Form and Function. American Journal of Human Genetics, 2002, 70, 829-844.	2.6	432
482	Novel germlineCDH1mutations in hereditary diffuse gastric cancer families. Human Mutation, 2002, 19, 518-525.	1.1	63
483	Prevalence of germline mutations ofMLH1 andMSH2 in hereditary nonpolyposis colorectal cancer families from Spain. International Journal of Cancer, 2002, 98, 774-779.	2.3	41
484	Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. International Journal of Cancer, 2002, 99, 63-67.	2.3	162
485	Silencing of thePTENtumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes and Cancer, 2002, 35, 74-80.	1.5	94
486	Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nature Genetics, 2002, 32, 355-357.	9.4	402

#	Article	IF	Citations
487	Role of PTEN, a Lipid Phosphatase Upstream Effector of Protein Kinase B, in Epithelial Thyroid Carcinogenesis. Annals of the New York Academy of Sciences, 2002, 968, 213-221.	1.8	39
488	Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrettâ€™s oesophagus-associated adenocarcinoma. British Journal of Cancer, 2001, 84, 748-753.	2.9	13
489	Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma. American Journal of Human Genetics, 2001, 69, 49-54.	2.6	1,021
490	Germline Mutations in BMPR1A/ALK3 Cause a Subset of Cases of Juvenile Polyposis Syndrome and of Cowden and Bannayan-Riley-Ruvalcaba Syndromes*. American Journal of Human Genetics, 2001, 69, 704-711.	2.6	236
491	Germline SDHD mutation in familial phaeochromocytoma. Lancet, The, 2001, 357, 1181-1182.	6.3	236
492	Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet, The, 2001, 358, 210-211.	6.3	210
493	PTEN mutations and Proteus syndrome. Lancet, The, 2001, 358, 2079-2080.	6.3	59
494	Rapid Mutation Scanning of Genes Associated with Familial Cancer Syndromes Using Denaturing High-Performance Liquid Chromatography. Neoplasia, 2001, 3, 236-244.	2.3	31
495	Genetic Testing for Cancer Predisposition. Annual Review of Medicine, 2001, 52, 371-400.	5.0	103
496	The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome. Journal of Medical Genetics, 2001, 38, 52-58.	1.5	81
497	Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Annals of Oncology, 2001, 12, 1743-1747.	0.6	20
498	Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases. Human Genetics, 2001, 109, 146-151.	1.8	42
499	Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clinical Endocrinology, 2001, 55, 399-402.	1.2	65
500	Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma. Cancer, 2001, 91, 1451-1457.	2.0	45
501	Mutation analysis ofNTRK2 andNTRK3, encoding 2 tyrosine kinase receptors, in sporadic human medullary thyroid carcinoma reveals novel sequence variants. International Journal of Cancer, 2001, 92, 70-74.	2.3	15
502	Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease. Human Genetics, 2001, 108, 409-415.	1.8	17
503	To be or not to BMP. Nature Genetics, 2001, 28, 105-107.	9.4	32
504	Over-representation of a germline variant in the gene encoding RET co-receptor GFRÎ±-1 but not GFRÎ±-2 or GFRÎ±-3 in cases with sporadic medullary thyroid carcinoma. Oncogene, 2001, 20, 2161-2170.	2.6	29

#	Article	IF	Citations
505	RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene, 2001, 20, 7573-7577.	2.6	127
506	Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Human Molecular Genetics, 2001, 10, 1907-1913.	1.4	155
507	Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. Journal of Medical Genetics, 2001, 38, 824-833.	1.5	132
508	PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Human Molecular Genetics, 2001, 10, 599-604.	1.4	235
509	Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease. Gut, 2001, 48, 671-675.	6.1	73
510	Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 15044-15049.	3.3	399
511	PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Human Molecular Genetics, 2001, 10, 605-616.	1.4	177
512	Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Human Molecular Genetics, 2001, 10, 251-258.	1.4	79
513	Male breast cancer in Cowden syndrome patients with germline PTEN mutations. Journal of Medical Genetics, 2001, 38, 159-164.	1.5	160
514	PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Human Molecular Genetics, 2001, 10, 237-242.	1.4	202
515	Biallelic inactivating mutations and an occult germline mutation ofPTEN in primary cervical carcinomas. Genes Chromosomes and Cancer, 2000, 29, 166-172.	1.5	20
516	A bird's eye view of global methylation. Nature Genetics, 2000, 24, 101-102.	9.4	54
517	Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genetics, 2000, 26, 16-17.	9.4	420
518	Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene, 2000, 19, 2060-2066.	2.6	160
519	Multiple endocrine neoplasia type 2 and the practice of molecular medicine. Reviews in Endocrine and Metabolic Disorders, 2000, 1, 283-290.	2.6	42
520	Expression of the PTEN tumour suppressor protein during human development. Human Molecular Genetics, 2000, 9, 1633-1639.	1.4	73
521	Will the real Cowden syndrome please stand up: revised diagnostic criteria. Journal of Medical Genetics, 2000, 37, 828-830.	1.5	483
522	Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Human Molecular Genetics, 2000, 9, 765-768.	1.4	188

#	Article	IF	Citations
523	Familial Papillary Thyroid Cancerâ€"Many Syndromes, Too Many Genes?*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1755-1757.	1.8	52
524	Differential Genetic Alterations in von Hippel-Lindau Syndrome-Associated and Sporadic Pheochromocytomas1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4568-4574.	1.8	79
525	Changes in EndometrialPTENExpression throughout the Human Menstrual Cycle1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2334-2338.	1.8	95
526	Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers. Journal of the National Cancer Institute, 2000, 92, 924-930.	3.0	709
527	Analysis of genetic and phenotypic heterogeneity in juvenile polyposis. Gut, 2000, 46, 656-660.	6.1	117
528	RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease. Journal of Medical Genetics, 2000, 37, 572-578.	1.5	93
529	Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation. American Journal of Pathology, 2000, 157, 1123-1128.	1.9	254
530	Differential Nuclear and Cytoplasmic Expression of PTEN in Normal Thyroid Tissue, and Benign and Malignant Epithelial Thyroid Tumors. American Journal of Pathology, 2000, 156, 1693-1700.	1.9	283
531	Familial Papillary Thyroid Cancer--Many Syndromes, Too Many Genes?. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1755-1757.	1.8	40
532	Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Research, 2000, 60, 6822-5.	0.4	206
533	Differences in Allelic Distribution of Two Polymorphisms in the VHL-Associated GeneCUL2in Pheochromocytoma Patients without SomaticCUL2Mutations1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3207-3211.	1.8	11
534	PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Human Molecular Genetics, 1999, 8, 185-193.	1.4	254
535	Specific polymorphisms in the RETproto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. Journal of Medical Genetics, 1999, 36, 771-774.	1.5	142
536	Mutation Analysis Reveals Novel Sequence Variants inNTRK1in Sporadic Human Medullary Thyroid Carcinoma¹. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2784-2787.	1.8	22
537	PTEN Mutation Spectrum and Genotype-Phenotype Correlations in Bannayan-Riley-Ruvalcaba Syndrome Suggest a Single Entity With Cowden Syndrome. Human Molecular Genetics, 1999, 8, 1461-1472.	1.4	562
538	Mutations in the endothelin-receptor B gene in Hirschsprung disease in Sweden. Clinical Genetics, 1999, 55, 215-217.	1.0	12
539	Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene, 1999, 18, 1369-1373.	2.6	137
540	Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. British Journal of Cancer, 1999, 79, 718-723.	2.9	119

#	Article	IF	Citations
541	Genomic organization and chromosomal localization of the humanCUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. , 1999, 26, 20-28.		20
542	Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. , 1999, 26, 322-328.		38
543	No evidence for germlinePTEN mutations in families with breast and brain tumours. , 1999, 84, 216-219.		18
544	Long-chain L 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency does not appear to be the primary cause of lipid myopathy in patients with Bannayan-Riley-Ruvalcaba syndrome (BRRS). , 1999, 83, 3-5.		9
545	Loss-of-Function Mutations in PPARÎ³ Associated with Human Colon Cancer. Molecular Cell, 1999, 3, 799-804.	4.5	485
546	Interpretation of Genetic Test Results for Hereditary Nonpolyposis Colorectal Cancer. JAMA - Journal of the American Medical Association, 1999, 282, 247.	3.8	118
547	The role of PTEN, a phosphatase gene, in inherited and sporadic nonmedullary thyroid tumors. Endocrine Reviews, 1999, 54, 441-52; discussion 453.	7.1	14
548	PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Research, 1999, 59, 5808-14.	0.4	178
549	Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene, 1998, 16, 1743-1748.	2.6	205
550	Genomic structure and chromosomal localization of the human GDNFR-Î± gene. Oncogene, 1998, 16, 597-601.	2.6	15
551	PTEN mutations in gliomas and glioneuronal tumors. Oncogene, 1998, 16, 2259-2264.	2.6	300
552	A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene, 1998, 16, 2403-2406.	2.6	92
553	Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene, 1998, 17, 727-731.	2.6	57
554	PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene, 1998, 16, 2879-2883.	2.6	122
555	PTEN and inherited hamartoma-cancer syndromes. Nature Genetics, 1998, 19, 223-223.	9.4	70
556	Deletion-insertion mutation encompassing RET codon 634 is associated with medullary thyroid carcinoma. Human Mutation, 1998, 11, S3-S4.	1.1	9
557	GermlinePTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba Syndrome. American Journal of Medical Genetics Part A, 1998, 80, 399-402.	2.4	105
558	Allelic imbalance, including deletion ofPTEN/MMAC1, at the Cowden disease locus on 10q22-23, in hamartomas from patients with cowden syndrome and germlinePTEN mutation. , 1998, 21, 61-69.		85

#	Article	IF	Citations
559	Investigation of the genes for RET and its ligand complex, GDNF/GFRÎ±-1, in small cell lung carcinoma. , 1998, 21, 326-332.		16
560	Analysis of the PTEN gene in human meningiomas. Neuropathology and Applied Neurobiology, 1998, 24, 3-8.	1.8	55
561	Molecular Classification of the Inherited Hamartoma Polyposis Syndromes: Clearing the Muddied Waters. American Journal of Human Genetics, 1998, 62, 1020-1022.	2.6	80
562	Comprehensive mutational scanning of the p53 coding region by two- dimensional gene scanning. Carcinogenesis, 1998, 19, 979-984.	1.3	25
563	Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype.. Journal of Medical Genetics, 1998, 35, 886-889.	1.5	83
564	Germline PTEN mutations in Cowden syndrome-like families.. Journal of Medical Genetics, 1998, 35, 881-885.	1.5	140
565	Molecular Analysis of theretandGDNFGenes in a Family with Multiple Endocrine Neoplasia Type 2A and Hirschsprung Disease1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3361-3364.	1.8	61
566	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Human Molecular Genetics, 1998, 7, 507-515.	1.4	578
567	Rapid design of denaturing gradient-based two-dimensional electrophoretic gene mutational scanning tests. Nucleic Acids Research, 1998, 26, 2398-2406.	6.5	43
568	Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of cases. Human Molecular Genetics, 1998, 7, 1907-1912.	1.4	142
569	Genetics of Cowden syndrome: through the looking glass of oncology.. International Journal of Oncology, 1998, 12, 701-10.	1.4	65
570	Low frequency of RET mutations in Hirschsprung disease in Sweden. Clinical Genetics, 1998, 54, 39-44.	1.0	41
571	Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba Syndrome. , 1998, 80, 399.		3
572	Germline Dinucleotide Mutation in Codon 883 of theRETProto-Oncogene in Multiple Endocrine Neoplasia Type 2B Without Codon 918 Mutation. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3902-3904.	1.8	216
573	Mutation Analysis of Glial Cell Line-Derived Neurotrophic Factor, a Ligand for an RET/Coreceptor Complex, in Multiple Endocrine Neoplasia Type 2 and Sporadic Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3025-3028.	1.8	26
574	Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Human Molecular Genetics, 1997, 6, 1051-1056.	1.4	102
575	P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9052-9057.	3.3	765
576	Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genetics, 1997, 16, 64-67.	9.4	1,902

#	Article	IF	Citations
577	The Role of MMAC1 Mutations in Early-Onset Breast Cancer: Causative in Association with Cowden Syndrome and Excluded in BRCA1-Negative Cases. American Journal of Human Genetics, 1997, 61, 1036-1043.	2.6	128
578	The expression of RET and its multiple splice forms in developing human kidney. Oncogene, 1997, 14, 1811-1818.	2.6	35
579	Genetic testing: The problems and the promise. Nature Biotechnology, 1997, 15, 422-426.	9.4	94
580	Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nature Genetics, 1997, 16, 333-334.	9.4	622
581	Cowden Syndrome. Journal of Genetic Counseling, 1997, 6, 181-192.	0.9	99
582	Genetic screening in hereditary medullary thyroid carcinoma. Acta Chirurgica Austriaca, 1997, 29, 5-8.	0.2	3
583	Ret in human development and oncogenesis. BioEssays, 1997, 19, 389-395.	1.2	74
584	Mutations of theRET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. , 1997, 9, 97-109.		180
585	Mutations of the RET protoâ€oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Human Mutation, 1997, 9, 97-109.	1.1	17
586	Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	9.4	425
587	Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma. British Journal of Cancer, 1996, 74, 339-341.	2.9	11
588	Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clinical Endocrinology, 1996, 44, 249-257.	1.2	209
589	Localization of the gene for Cowden disease to chromosome 10q22â€“23. Nature Genetics, 1996, 13, 114-116.	9.4	630
590	Germline mutations of the RET ligand GDNF are not sufficient to cause Hirschsprung disease. Nature Genetics, 1996, 14, 345-347.	9.4	203
591	Mutational scanning of large genes by extensive PCR multiplexing and two-dimensional electrophoresis: application to the RB1 gene. Human Molecular Genetics, 1996, 5, 755-761.	1.4	30
592	TheRETProto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease. New England Journal of Medicine, 1996, 335, 943-951.	13.9	317
593	The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA - Journal of the American Medical Association, 1996, 276, 1575-1579.	3.8	516
594	Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Research, 1996, 56, 2167-70.	0.4	120

#	Article	IF	Citations
595	The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA - Journal of the American Medical Association, 1996, 276, 1575-9.	3.8	289
596	No mutation at codon 918 of the RET gene in a family with multiple endocrine neoplasia type 2B. Clinical Endocrinology, 1995, 43, 759-762.	1.2	16
597	Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clinical Endocrinology, 1995, 43, 123-127.	1.2	171
598	Mutation of theRET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes and Cancer, 1995, 12, 209-212.	1.5	160
599	Presymptomatic genetic screening in families with multiple endocrine neoplasia type 2. Journal of Molecular Medicine, 1995, 73, 229-33.	1.7	12
600	Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature, 1995, 373, 536-539.	13.7	932
601	Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas.. Journal of Medical Genetics, 1995, 32, 934-937.	1.5	144
602	A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene, 1995, 10, 509-13.	2.6	172
603	Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Human Molecular Genetics, 1994, 3, 237-241.	1.4	540
604	Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy?. Journal of Medical Genetics, 1994, 31, 458-461.	1.5	101
605	Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes and Hirschsprung disease. Journal of Cell Science, 1994, 1994, 43-49.	1.2	37
606	Haplotype analysis of MEN 2 mutations. Human Molecular Genetics, 1994, 3, 1771-1774.	1.4	27
607	Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Human Molecular Genetics, 1994, 3, 2163-2168.	1.4	239
608	A 7 bp deletion of the RET proto-oncogene in familial Hirschsprungâ€˜s disease. Human Molecular Genetics, 1994, 3, 1439-1440.	1.4	19
609	A novel polymorphism in the coding sequence of the human RET proto-oncogene. Human Genetics, 1994, 94, 579-80.	1.8	12
610	Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genetics, 1994, 6, 70-74.	9.4	647
611	Familial cancer syndromes. Lancet, The, 1994, 343, 709-713.	6.3	38
612	De-novo mutations of the RET proto-oncogene in Hirschsprung's disease. Lancet, The, 1994, 344, 1769-1770.	6.3	24

#	Article	IF	Citations
613	Meningeal carcinomatosis from transitional cell carcinoma of the bladder. Cancer, 1993, 72, 553-557.	2.0	30
614	Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature, 1993, 363, 458-460.	13.7	1,886
615	Mortality From Second Tumors Among Long-Term Survivors of Retinoblastoma. Journal of the National Cancer Institute, 1993, 85, 1121-1128.	3.0	553
616	The role of gene mutations in the genesis of familial cancers. FASEB Journal, 1993, 7, 910-919.	0.2	48
617	Familial Barrett esophagus and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiology Biomarkers and Prevention, 1993, 2, 397-9.	1.1	19
618	BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. , 0, .		11
619	Mutation Analysis of Glial Cell Line-Derived Neurotrophic Factor, a Ligand for an RET/Coreceptor Complex, in Multiple Endocrine Neoplasia Type 2 and Sporadic Neuroendocrine Tumors. , 0, .		10
620	Balanced Translocation of 10q and 13q, Including the PTENGene, in a Boy with a Human Chorionic Gonadotropin-Secreting Tumor and the Bannayan-Riley-Ruvalcaba Syndrome. , 0, .		7